These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31761402)

  • 1. Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study.
    Vedovati MC; Mancuso A; Pierpaoli L; Paliani U; Conti S; Ascani A; Galeotti G; Di Filippo F; Caponi C; Agnelli G; Becattini C
    Int J Cardiol; 2020 Feb; 301():167-172. PubMed ID: 31761402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study.
    Riva N; Bellesini M; Di Minno MN; Mumoli N; Pomero F; Franchini M; Fantoni C; Lupoli R; Brondi B; Borretta V; Bonfanti C; Ageno W; Dentali F
    Thromb Haemost; 2014 Sep; 112(3):511-21. PubMed ID: 24899092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
    Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
    Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE study.
    Guman NAM; Becking AL; Weijers SS; Kraaijpoel N; Mulder FI; Carrier M; Jara-Palomares L; Di Nisio M; Ageno W; Beyer-Westendorf J; Klok FA; Vanassche T; Otten JMMB; Cosmi B; Peters MJL; Wolde MT; Delluc A; Sanchez-Lopez V; Porreca E; Bossuyt PMM; Gerdes VEA; Büller HR; van Es N; Kamphuisen PW
    J Thromb Haemost; 2024 Sep; 22(9):2470-2481. PubMed ID: 38866248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism.
    Palareti G; Antonucci E; Mastroiacovo D; Ageno W; Pengo V; Poli D; Testa S; Tosetto A; Prandoni P
    J Thromb Haemost; 2018 Oct; 16(10):1994-2002. PubMed ID: 30059189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal Changes in Long-Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era.
    Kaneda K; Yamashita Y; Morimoto T; Chatani R; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Takada T; Otsui K; Sakamoto J; Ogihara Y; Inoue T; Usami S; Chen PM; Togi K; Koitabashi N; Hiramori S; Doi K; Mabuchi H; Tsuyuki Y; Murata K; Takabayashi K; Nakai H; Sueta D; Shioyama W; Dohke T; Nishikawa R; Ono K; Kimura T
    J Am Heart Assoc; 2024 Aug; 13(15):e034412. PubMed ID: 39082425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population.
    Pilkerton CS; Adelman M; Crocetti E; Xiang J; Strick V; Ponte CD; Peckens S; Jackson BP; Whipp K; Ashcraft AM
    Ann Pharmacother; 2024 Aug; 58(8):781-789. PubMed ID: 37994550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
    Klok FA; Barco S; Konstantinides SV
    Thromb Haemost; 2017 Jun; 117(6):1164-1170. PubMed ID: 28276566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
    Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
    Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
    Campello E; Spiezia L; Simion C; Tormene D; Camporese G; Dalla Valle F; Poretto A; Bulato C; Gavasso S; Radu CM; Simioni P
    J Am Heart Assoc; 2020 Dec; 9(23):e018917. PubMed ID: 33222589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism.
    Frei AN; Stalder O; Limacher A; Méan M; Baumgartner C; Rodondi N; Aujesky D
    Thromb Haemost; 2021 Nov; 121(11):1512-1522. PubMed ID: 33930905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients.
    Christen JR; Bertolino J; Jean E; Camoin L; Ebbo M; Harlé JR; Schleinitz N; Sarlon G; Bernit E
    Hemoglobin; 2019; 43(4-5):296-299. PubMed ID: 31724442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism.
    Scherz N; Méan M; Limacher A; Righini M; Jaeger K; Beer HJ; Frauchiger B; Osterwalder J; Kucher N; Matter CM; Banyai M; Angelillo-Scherrer A; Lämmle B; Husmann M; Egloff M; Aschwanden M; Bounameaux H; Cornuz J; Rodondi N; Aujesky D
    J Thromb Haemost; 2013 Mar; 11(3):435-43. PubMed ID: 23279158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
    Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
    J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study.
    Malec K; Broniatowska E; Undas A
    Lupus; 2020 Jan; 29(1):37-44. PubMed ID: 31757182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.